KILL KINETICS AND REGROWTH PATTERNS OF ESCHERICHIA-COLI EXPOSED TO GENTAMICIN CONCENTRATION-TIME PROFILES SIMULATING INVIVO BOLUS AND INFUSION DOSING

被引:34
作者
BASTONE, EB
LI, SC
IOANNIDESDEMOS, LI
SPICER, WJ
MCLEAN, AJ
机构
[1] ALFRED HOSP,DEPT CLIN PHARMACOL,COMMERCIAL RD,PRAHRAN,VIC 3181,AUSTRALIA
[2] ALFRED HOSP,DEPT PHARM,PRAHRAN,VIC 3181,AUSTRALIA
[3] ALFRED HOSP,DEPT MICROBIOL & INFECT DIS,PRAHRAN,VIC 3181,AUSTRALIA
[4] MONASH UNIV,ALFRED HOSP,DEPT MED,MELBOURNE,VIC 3181,AUSTRALIA
关键词
D O I
10.1128/AAC.37.4.914
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The relative influence of peak concentration (C(max)) versus the area under the antibiotic concentration-time curve (AUC) on the bactericidal effect of gentamicin against Escherichia coli NCTC 10418 was studied. Bacteria in the lag phase were exposed to an in vitro gentamicin concentration series which mirrored the concentrations determined in patients after 80-mg intravenous bolus (1 min) and 80-mg intravenous infusion (30 min) doses. Bacterial viable cell counts and gentamicin concentrations were measured before and during antibiotic exposure. Both the C(max) and AUC were shown to be factors determining antibacterial activity; however, the C(max) was an independent determinant of effect. These findings indicate that bolus intravenous dosing with gentamicin could maximize bactericidal activity. Increased efficacy could result at any given daily antibiotic dose if delivered via bolus with long intervals (12 to 24 h) between doses if appropriate precautions to avoid toxicity are taken.
引用
收藏
页码:914 / 917
页数:4
相关论文
共 22 条
[1]  
BAILEY RR, 1974, LANCET, V1, P730
[2]  
BERGERON MG, 1978, INFECTION S1, V6, P38
[3]   COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE [J].
BLASER, J ;
STONE, BB ;
GRONER, MC ;
ZINNER, SH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1054-1060
[4]  
BOSCH DE, 1990, CLIN PHARMACY, V9, P777
[5]   INTRAVENOUS-INJECTION OF GENTAMICIN AND TOBRAMYCIN WITHOUT IMPAIRMENT OF HEARING [J].
DOBBS, SM ;
MAWER, GE .
JOURNAL OF INFECTIOUS DISEASES, 1976, 134 :S114-S117
[6]   CONTINUOUS VS DISCONTINUOUS THERAPY WITH PENICILLIN - THE EFFECT OF THE INTERVAL BETWEEN INJECTIONS ON THERAPEUTIC EFFICACY [J].
EAGLE, H ;
FLEISCHMAN, R ;
LEVY, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1953, 248 (12) :481-488
[7]   EFFECT OF SCHEDULE OF ADMINISTRATION ON THE THERAPEUTIC EFFICACY OF PENICILLIN - IMPORTANCE OF THE AGGREGATE TIME PENICILLIN REMAINS AT EFFECTIVELY BACTERICIDAL LEVELS [J].
EAGLE, H ;
FLEISCHMAN, R ;
MUSSELMAN, AD .
AMERICAN JOURNAL OF MEDICINE, 1950, 9 (03) :280-299
[8]   IMPACT OF DOSING INTERVALS ON ACTIVITY OF GENTAMICIN AND TICARCILLIN AGAINST PSEUDOMONAS-AERUGINOSA IN GRANULOCYTOPENIC MICE [J].
GERBER, AU ;
CRAIG, WA ;
BRUGGER, HP ;
FELLER, C ;
VASTOLA, AP ;
BRANDEL, J .
JOURNAL OF INFECTIOUS DISEASES, 1983, 147 (05) :910-917
[9]   ANTIBIOTIC-THERAPY OF INFECTIONS DUE TO PSEUDOMONAS-AERUGINOSA IN NORMAL AND GRANULOCYTOPENIC MICE - COMPARISON OF MURINE AND HUMAN PHARMACOKINETICS [J].
GERBER, AU ;
BRUGGER, HP ;
FELLER, C ;
STRITZKO, T ;
STALDER, B .
JOURNAL OF INFECTIOUS DISEASES, 1986, 153 (01) :90-97
[10]   CONSTANT INFUSIONS VS INTERMITTENT DOSES OF GENTAMICIN AGAINST PSEUDOMONAS-AERUGINOSA INVITRO [J].
GERBER, AU ;
WIPRACHTIGER, P ;
STETTLERSPICHIGER, U ;
LEBEK, G .
JOURNAL OF INFECTIOUS DISEASES, 1982, 145 (04) :554-560